SCHEMBL4106222

SCHEMBL4106222

CC(C)N(CCN(CCNC(=O)Nc1ccccc1)C(=O)Nc1ccc(C(F)(F)F)cc1)C(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ MTOR P42345 3/20 0.47
▸ MCHR1 Q99705 1/20 0.47
▸ CNR1 P21554 1/20 0.44
▸ GOT1 P17174 1/20 0.44
▸ FPR2 P25090 1/20 0.43
▸ EPHX2 P34913 2/20 0.43
▸ PSMB5 P28074 1/20 0.42
▸ IDH1 O75874 1/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA4 P22748 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ MAPT P10636 3/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ HTT P42858 2/20 0.42
▸ CCR3 P51677 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4111552 0.96 MEN1 (0.56) MEN1KMT2AMTORMCHR1CNR1
SCHEMBL4119984 0.91 MEN1 (0.51) MEN1KMT2AMTORMCHR1CNR1
SCHEMBL4112236 0.91 CNR1 (0.56) MEN1KMT2AMTORMCHR1CNR1
SCHEMBL4114155 0.89 MEN1 (0.49) MEN1KMT2AMCHR1CNR1FPR2
SCHEMBL4107298 0.88 MEN1 (0.55) MEN1KMT2AMTORMCHR1CNR1
SCHEMBL4115328 0.86 MCHR1 (0.61) MEN1KMT2AMTORMCHR1CNR1
SCHEMBL4119609 0.84 MEN1 (0.53) MEN1KMT2AMTORMCHR1CNR1
SCHEMBL4112186 0.83 MEN1 (0.60) MEN1KMT2AMTORMCHR1CNR1
SCHEMBL4108313 0.83 CNR1 (0.56) MEN1KMT2AMTORMCHR1CNR1
SCHEMBL4114182 0.82 MCHR1 (0.59) MEN1KMT2AMTORMCHR1CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118330-A1 Diurea derivatives ACTIVE BIOTECH AB (SE) 2009-05-07 — — US claimed
EP-1711175-A1 DIUREA DERIVATIVES Active Biotech AB (SE) 2006-10-18 — — EP claimed
WO-2005074919-A1 DIUREA DERIVATIVES ACTIVE BIOTECH AB (SE) 2005-08-18 — — WO claimed
US-20090118330-A1 Diurea derivatives ACTIVE BIOTECH AB (SE) 2009-05-07 — — US disclosed
EP-1711175-A1 DIUREA DERIVATIVES Active Biotech AB (SE) 2006-10-18 — — EP disclosed
WO-2005074919-A1 DIUREA DERIVATIVES ACTIVE BIOTECH AB (SE) 2005-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118330-A1 Diurea derivatives IL2, CASP2, MAVS MEN1 4167/4885KMT2A 2720/4885MTOR 393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback